Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Brian Ossenbeck initiated a cautious outlook for the North American truckload sector, saying he believes "tepid" freight demand and a lack of a boost to consumer spending from low gas prices will lead the first contraction in realized revenue per loaded mile since 2007. Ossenteck initiated Werner (WERN) with an Overweight rating due to expectations that its diversification will drive a re-rating of its shares. The analyst set a Neutral rating on Swift Transport (SWFT) and Ryder (R), and an Underweight rating on Heartland Express (HTLD) and Knight Transportation (KNX). 2. Editas Medicine (EDIT) initiated with an Outperform at Cowen and JMP Securities, and a Neutral at JPMorgan. Cowen cited the company's "world-class expertise" in CRISPR, which will enable the development of a broad pipeline. JPMorgan analyst Cory Kasimov added that the company's CRISPR gene editing platform has the potential to be a game changer, but that it has "limited value-inflecting news" likely to come in 2016. 3. BeiGene (BGNE) initiated with an Outperform at Cowen citing the proof-of-concept data on each of four clinical candidates and expects to monetize those assets on the global stage. The company was also initiated with an Overweight and a Buy at Morgan Stanley and Goldman, respectively. 4. Nielsen (NLSN) initiated with a Buy at Jefferies by analyst Ryan Cary, who said the company is well positioned to benefit from demand for cross-platform viewership measurement and greenfield in emerging markets provides protection against macro headwinds. 5. Square (SQ) initiated with a Sector Weight at Pacific Crest by analyst Josh Beck, who said his optimism is balanced by the market's high expectations for execution, the uncertain regulatory environment for SMB lending, and software initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.

BeiGene announced that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use. "Tislelizumab is foundational for BeiGene's solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "Today's EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the world."